This session delivers a thorough exploration of device-aided therapies (DATs) for advanced Parkinson’s disease, designed to provide balanced, practical insights for clinicians. Starting with an overview of existing DAT options—including DUODOPA, , DBS and Apomorphine . The session outlines the spectrum of available therapeutic strategies, highlighting their mechanisms, advantages, and clinical considerations.
A session will introduce of VYALEV 9 VYALEV (Foslevodopa/Foscarbidopa), including its novel mechanism of action and the innovative VYAFUSER delivery device, to ensure participants are equipped with up-to-date information on emerging solutions. The session also emphasizes real-world patient selection, providing practical guidance on identifying candidates for referral. Discussion will address key factors impacting referral decisions, such as symptom profiles, prior treatments, patient preferences, and care goals.